Bioventus (NASDAQ:BVS) Issues FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.7 million.

Bioventus Stock Down 2.3%

Bioventus stock traded down $0.25 during mid-day trading on Thursday, reaching $10.67. The stock had a trading volume of 561,497 shares, compared to its average volume of 375,591. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The stock’s 50-day simple moving average is $9.28 and its 200-day simple moving average is $8.19. The firm has a market capitalization of $887.21 million, a PE ratio of 32.38 and a beta of 0.72.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts forecast that Bioventus will post 0.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BVS has been the topic of a number of recent research reports. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. CJS Securities initiated coverage on Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price on the stock. Craig Hallum raised their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Barrington Research raised their target price on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Bioventus has a consensus rating of “Buy” and a consensus target price of $14.00.

Insider Buying and Selling

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the sale, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 33.00% of the company’s stock.

Key Headlines Impacting Bioventus

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Q1 earnings beat: Bioventus reported EPS of $0.15 vs. the consensus $0.09 and revenue of $132.09M, a clear upside to street expectations that supports near?term earnings momentum. Read More.
• Positive Sentiment: FY?2026 EPS guidance in line to slightly above consensus: management set EPS guidance of $0.750–$0.790 (consensus ~$0.750), giving some visibility to full?year profitability and validating the beat. Read More.
• Neutral Sentiment: Company disclosure and investor materials are available: earnings call transcript and slide deck provide management color on drivers and execution — useful for assessing sustainability of the beat. Read More. • Read More.
• Neutral Sentiment: Trading context: volume is roughly in line with average and the stock remains nearer its 52?week high than low; investors should weigh one quarter’s beat against valuation (PE ~32.5). Read More.
• Negative Sentiment: Profitability and leverage are concerns: net margin was ~4.0% and debt?to?equity about 1.22 — modest margins and leverage limit upside unless revenue growth or margin expansion accelerates. Read More.

Institutional Trading of Bioventus

Hedge funds have recently bought and sold shares of the business. Prelude Capital Management LLC bought a new stake in Bioventus during the third quarter worth $74,000. Mercer Global Advisors Inc. ADV bought a new stake in Bioventus during the third quarter worth $78,000. Brooklyn Investment Group bought a new stake in shares of Bioventus in the fourth quarter valued at $91,000. O Shaughnessy Asset Management LLC bought a new stake in shares of Bioventus in the fourth quarter valued at $99,000. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Bioventus in the third quarter valued at $96,000. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.